Alkermes Completes Acquisition of Avadel Pharmaceuticals

Reuters

Feb 12

Alkermes Completes Acquisition of Avadel Pharmaceuticals

Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, adding Avadel’s FDA-approved product, LUMRYZ®, to its portfolio and expanding its presence in the sleep medicine market. The deal is supported by approximately $775 million in cash and $1.525 billion in term loans due in 2031. Alkermes expects to pay down the debt quickly with business cash flows and plans to provide 2026 financial expectations for the combined organization in February 2026. The company will record $40 million in transaction-related costs and approximately $180 million in LUMRYZ inventory fair value step-up in 2026. Alkermes highlighted the acquisition as a significant step in its strategy to accelerate growth in sleep medicine and strengthen its commercial capabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260211590882) on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610925121"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610925121\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610925121?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610925121","market":"nz","top_or_hot":-1,"title":"Alkermes Completes Acquisition of Avadel Pharmaceuticals","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alkermes Completes Acquisition of Avadel Pharmaceuticals\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alkermes plc has completed its acquisition of <a href=\"https://laohu8.com/S/AVDL\">Avadel Pharmaceuticals plc</a>, adding Avadel’s FDA-approved product, LUMRYZ®, to its portfolio and expanding its presence in the sleep medicine market. The deal is supported by approximately $775 million in cash and $1.525 billion in term loans due in 2031. Alkermes expects to pay down the debt quickly with business cash flows and plans to provide 2026 financial expectations for the combined organization in February 2026. The company will record $40 million in transaction-related costs and approximately $180 million in LUMRYZ inventory fair value step-up in 2026. Alkermes highlighted the acquisition as a significant step in its strategy to accelerate growth in sleep medicine and strengthen its commercial capabilities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260211590882) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alkermes Completes Acquisition of Avadel Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlkermes Completes Acquisition of Avadel Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-12 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alkermes Completes Acquisition of Avadel Pharmaceuticals\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alkermes plc has completed its acquisition of <a href=\"https://laohu8.com/S/AVDL\">Avadel Pharmaceuticals plc</a>, adding Avadel’s FDA-approved product, LUMRYZ®, to its portfolio and expanding its presence in the sleep medicine market. The deal is supported by approximately $775 million in cash and $1.525 billion in term loans due in 2031. Alkermes expects to pay down the debt quickly with business cash flows and plans to provide 2026 financial expectations for the combined organization in February 2026. The company will record $40 million in transaction-related costs and approximately $180 million in LUMRYZ inventory fair value step-up in 2026. Alkermes highlighted the acquisition as a significant step in its strategy to accelerate growth in sleep medicine and strengthen its commercial capabilities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260211590882) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVDL","symbol_name":"Avadel Pharmaceuticals plc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL57NhN6:1","article_id":"2610925121","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610925121","pubTimestamp":1770899458,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, adding Avadel’s FDA-approved product, LUMRYZ, to its portfolio and expanding its presence in the sleep medicine market. The deal is supported by approximately $775 million in cash and $1.525 billion in term loans due in 2031. Alkermes expects to pay down the debt quickly with business cash flows and plans to provide 2026 financial expectations for the combined organization in February 2026. The company will record $40 million in transaction-related costs and approximately $180 million in LUMRYZ inventory fair value step-up in 2026. Alkermes highlighted the acquisition as a significant step in its strategy to accelerate growth in sleep medicine and strengthen its commercial capabilities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVDL":"Avadel Pharmaceuticals plc","ALKS":"阿尔凯默斯","BK4007":"制药","BK4139":"生物科技"},"translate_title":"Alkermes完成对Avadel制药公司的收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVDL":0.9,"ALKS":0.9},"content_text":"Alkermes Completes Acquisition of Avadel Pharmaceuticals\n    \n\n        Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, adding Avadel’s FDA-approved product, LUMRYZ®, to its portfolio and expanding its presence in the sleep medicine market. The deal is supported by approximately $775 million in cash and $1.525 billion in term loans due in 2031. Alkermes expects to pay down the debt quickly with business cash flows and plans to provide 2026 financial expectations for the combined organization in February 2026. The company will record $40 million in transaction-related costs and approximately $180 million in LUMRYZ inventory fair value step-up in 2026. Alkermes highlighted the acquisition as a significant step in its strategy to accelerate growth in sleep medicine and strengthen its commercial capabilities.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260211590882) on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}